Business
Trevi Therapeutics to Attend Multiple Conferences in January 2022
11th Annual LifeSci Partners Corporate Access Event, January 5-7 Dermatology Summit, January 7 H.C. Wainwright BIOCONNECT Virtual Conference, January 10-13
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"11th Annual LifeSci Partners Corporate Access Event, January 5-7\n Dermatology Summit, January 7\n H.C. Wainwright BIOCONNECT Virtual Conference, January 10-13\n Biotech Showcase 2022, January 10-12 and January 17-19\n\n\nNEW HAVEN, Conn., Dec. 16, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that senior management will be participating in the 11th Annual LifeSci Partners Corporate Access Event taking place virtually from January 5-7, the Dermatology Summit taking place virtually on January 7, the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13 as well as the Biotech Showcase 2022 taking place virtually from January 10-12 and January 17-19.\n\n \n \n \n \n \n \n\n \nTrevi Therapeutics' senior leadership will participate in multiple conferences in January 2022 11th Annual LifeSci Partners Corporate Access EventThe senior management team will be hosting virtual one-on-one meetings. To register, visit LifeSci Partners Corporate Access Event 2022.\nDermatology Summit on Advancing Innovation in DermatologyJennifer Good, President and CEO, will be participating in the live panel discussion \"Emerging and Future Therapeutic Development for Itch\" moderated by Dr. Brian Kim on January 7 at 2:10 p.m. EST.\nH.C. Wainwright BIOCONNECT Virtual ConferenceThe management team will present virtually as well as host investor meetings for registered attendees.\nBiotech Showcase 2022The Company will have a virtual presentation on the conferences' online platform which can be accessed by registered attendees for the duration of the conference. Senior leadership will also participate in investor and ex-US partnership meetings throughout the course of the conference.\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi i...